Introduction
============

Particulate matter (PM) exposure contributes to an estimated 3.7 million annual deaths worldwide.^[@b1]^ According to the American Heart Association, PM exposure is a modifiable primary contributor to cardiovascular morbidity and mortality, often resulting from acute cardiovascular effects after short‐term exposure peaks.^[@b2]^ The major sources of short‐term fine particles (PM~2.5~) pollution are combustion activities (motor vehicles, power generation, and industrial processes), biomass burning, and other human activities such as heating and cooking.^[@b2]^ Because prevention of exposure to PM is particularly challenging---more than 80% of people in the United States receive some exposure---it is essential to identify modifiable factors that contribute to individual susceptibility to cardiac effects to aid the development of effective interventions.

Short‐term PM exposure has been associated with reduced heart rate variability (HRV) through epidemiological studies.^[@b3]--[@b4]^ Impaired autonomic modulation of the rhythmic activity of the sinus node, as reflected in reduced HRV, represents a pathophysiologic mechanism by which air pollution may lead to cardiac mortality, especially among older individuals.^[@b5]--[@b6]^ Notably, HRV shows wide interindividual variability, as well as highly variable responses to PM exposure.^[@b7]^ Therefore, HRV is an ideal early surrogate marker of cardiovascular autonomic dysfunction for identifying underlying factors that may modify susceptibility to cardiovascular effects of PM exposure. Furthermore, growing evidence indicates that systemic inflammation exacerbates HRV disturbances following PM exposure.^[@b8]^ PM with aerodynamic diameter \<2.5 μm (PM~2.5~) is especially deleterious because it penetrates into the alveoli and may act as a stimulus to trigger local cytokine production and systemic inflammation.^[@b9]^ Thus, immunoregulation is critical to limiting immune‐mediated cardiovascular pathology.^[@b10]^

Molecules involved in immunoresponses are attractive as potential modulators of cardiovascular pathology following PM exposure. Toll‐like receptors (TLRs), a group of receptors abundantly expressed on leukocytes, have emerged as crucial first‐responders linking innate and adaptive immunity after environmental challenge.^[@b11]^ *Toll‐like receptor 2* (*TLR2*), in particular, is a unique TLR family member that not only assists the clearance of bacterial components contained in PM via pathogen recognition^[@b12]^ but also modulates the expansion and behavior of regulatory T cells, which are the dominant circulating regulator of immunosuppression.^[@b13]--[@b14]^ *TLR2*‐related immunity is controlled through epigenetic mechanisms: Increased methylation in the *TLR2* promoter region is usually associated with *TLR2* silencing, while decreased methylation permits *TLR2* expression.^[@b15]^ Therefore, maintaining a proper methylation level of the *TLR2* gene is critical to ensure protective immunity.

Importantly, DNA methylation is reversible, thereby providing unique opportunities for modulation. This feature is critical, particularly for pathologies related to nonpreventable exposures, as it can offer potential interventions to ameliorate exposure‐related disease. Nutrients such as flavonoids and methyl nutrients can modify gene‐specific methylation in opposite directions.^[@b16]^ Flavonoids, the most common group of polyphenolic compounds in the human diet, can lower DNA methylation by reducing DNA methyltransferase activity.^[@b17]--[@b18]^ Methyl nutrients such as folic acid, vitamin B12, and methionine, on the other hand, may increase methylation by providing methyl donors.^[@b19]^ Thus, determining how such nutrients alter methylation states can provide insight that may be used to counteract exposure effects.

No study has yet investigated whether DNA methylation and nutrient intake may modify the cardiovascular effects of air pollution exposure. In this study, we hypothesized that programming of *TLR2* inactivation by increased methylation contributes to "epigenetic susceptibility" for immune‐mediated PM‐induced cardiovascular responses, as reflected in steeper reductions in HRV following short‐term PM~2.5~ exposure. We utilized the Normative Aging Study, a cohort of aging men in Eastern Massachusetts, to investigate the relationship between short‐term PM~2.5~ (48 hours) exposure and HRV, and to examine whether *TLR2* methylation in blood leukocytes modifies this relationship. We also examined the effect of flavonoid and methyl nutrients (folic acid, vitamin B12, and methionine) intakes on *TLR*2 methylation and explored their role as modifiers of the short‐term effects of ambient PM~2.5~ exposure on HRV. In addition to our primary hypothesis, we examined the effect of black carbon, carbon monoxide, nitrogen dioxide, and ozone on HRV, as well as the relationship between *TLR2* methylation and plasma inflammatory markers including interleukin 6 (IL‐6), IL‐8, IL‐1β, tumor necrosis factor α (TNF‐α), TNF‐γ, C‐reactive protein, intercellular adhesion molecule 1, and vascular endothelial growth factor.

Methods
=======

Study Population
----------------

The Normative Aging Study is an ongoing prospective cohort of older male participants established in Eastern Massachusetts by the U.S. Veterans Administration.^[@b20]^ For the present study, we excluded participants with incomplete data on PM~2.5~ exposure and HRV, leaving a total of 573 participants who were community‐dwelling men free of heart arrhythmias at examination ([Figure 1](#fig01){ref-type="fig"}). Participants were recalled for visits every 3 to 5 years, and we considered visits conducted since November 2000 (ie, the earliest date for which PM~2.5~ data were available) through 2011, for a total of 1275 visits (1 visit to 4 visits per participant; average 2.2 visits). Among the 573 participants, 500 participants had methylation data, 513 participants had flavonoid intake data, and 482 participants had methyl nutrients intake data. The study was approved by the institutional review boards of all participating institutions. All subjects provided informed consent.

![The study participants in the Normative Aging Study, 2000--2011. PM~2.5~ indicates particulate matter with aerodynamic diameter \<2.5 μm; *TLR2*,*Toll‐like receptor 2*. \*In each analysis, some additional participants may have been excluded due to missing key study variables. We have noted in each table the corresponding sample size.](jah3-4-e001423-g1){#fig01}

HRV Measurement
---------------

HRV was measured in the morning for 7 minutes with a 2‐channel electrocardiography monitor, and time‐domain variability and frequency‐domain variability of the heart rate were obtained as described previously.^[@b3]^ Observations with HRV measurement time \<3.5 minutes were excluded. The root mean square of successive differences (rMSSD) and standard deviation of normal‐to‐normal intervals (SDNN) were measured representing the time domain.^[@b21]^ Low‐frequency (LF) (0.04 to 0.15 Hz) and high‐frequency (HF) (0.15 to 0.4 Hz) power were used to represent the frequency domain.^[@b21]^

Blood *TLR2* Methylation and Plasma Inflammatory Markers
--------------------------------------------------------

*TLR2* methylation was analyzed on blood samples, collected after overnight fasting, at 5 CpG positions within the promoter region ([Figure 2](#fig02){ref-type="fig"}) using bisulfite‐treated pyrosequencing, as described previously.^[@b22]^ Exact positions and pyrosequencing primers were reported previously.^[@b20]^ The degree of methylation is reported as the ratio of methylated cytosines over the sum of methylated and unmethylated cytosines (%5mC). Plasma inflammatory markers including IL‐6, IL‐8, IL‐1β, TNF‐α, TNF‐γ, C‐reactive protein, intercellular adhesion molecule 1, and vascular endothelial growth factor were measured using previously described methods.^[@b20],[@b22]--[@b23]^

![Schematic view of the genomic structure and CpG dinucleotides selected for analysis in the *Toll‐like receptor 2* (*TLR2*) gene. The chromosomal location of the PCR amplicon for the *TLR2* gene pyrosequencing assay is based on the Human Genome Assembly 2009 (GRC37/hg19) (UCSC Genome Browser). The CpG island, gene promoter region, PSQ CpG sites, PCR primer, and PSQ sequence primer location are shown in the figure. TSS indicates the transcription start site; PCR, polymerase chain reaction; PSQ, pyrosequencing. Position 1: CpG154605258; Position 2: CpG154605262; Position 3: CpG154605264; Position 4: CpG154605272; Position 5: CpG154605276.](jah3-4-e001423-g2){#fig02}

Air Pollution and Weather Data
------------------------------

PM~2.5~ exposure levels across the study area were estimated based on a validated hybrid spatiotemporal prediction model,^[@b24]^ which was used in previous epidemiological studies.^[@b25]--[@b26]^ This exposure‐assessment method combined real physical measurements from the MODIS (Moderate Resolution Imaging Spectroradiometer) satellite--derived aerosol optical depth and classic land‐use regression methods to predict daily PM~2.5~ concentration levels across the Boston area from 2000 to 2011, at a 10×10‐km spatial resolution. Kloog and coauthors demonstrated that this method provides more accurate spatial resolution and unbiased predictions compared to prior models^[@b27]^ without compromising temporal resolution.^[@b28]^ For more methodological details of the prediction model please refer to Kloog et al.^[@b28]--[@b29]^ The 48‐hour PM~2.5~ moving averages before each examination were assigned based on the participants\' home addresses. The 48‐hour moving averages of outdoor apparent temperature was tabulated based on outdoor air temperature, relative humidity, and wind speed, which were obtained from the Boston airport weather station. Black carbon concentration was measured at the Harvard School of Public Health monitoring site, 1 km from the examination site, using an aethalometer (Magee Scientific, Berkeley, CA).^[@b30]^ Carbon monoxide, nitrogen dioxide, and ozone were obtained from the Massachusetts Department of Environmental Protection local monitoring sites, using a previously described method.^[@b30]^

FFQ and Nutrient Intake
-----------------------

At every visit, detailed information on the typical daily dietary intake of food and beverage items over the previous year was assessed with a self‐administered validated semiquantitative FFQ adapted from the questionnaire used in the Nurses\' Health Study. Details on the reproducibility and validity of this FFQ for estimating daily nutrient intakes,^[@b31]--[@b32]^ including flavonoid,^[@b33]^ and methyl nutrients (folic acid, vitamin B12, and methionine) intake,^[@b21]^ were published elsewhere. To estimate flavonoid intakes, we constructed a database for assessment of intake of the different flavonoid subclasses using the updated and expanded U.S. Department of Agriculture flavonoid content of foods and the proanthocyanidin databases together with other sources.^[@b34]--[@b35]^ Intakes of individual compounds were calculated as the sum of the consumption frequency of each food multiplied by the content of the specific flavonoid for the specified portion size. For foods in the FFQ for which there were no values available in the U.S. Department of Agriculture database, we searched a European database (EuroFIR eBASIS; <http://www.eurofir.org>) and other sources to ensure all available high‐quality data on flavonoid values could be included in the database. However, although these other sources served as a validation to the U.S. Department of Agriculture database, the addition of the EuroFIR data and the published literature did not contribute to more than 5% to 10% of the overall data used in the calculation of intakes for this analysis. For each participant and visit in this analysis, we derived average daily intakes (mg/day) at each visit of the subclasses commonly consumed in the U.S. diet. The specific subclasses included anthocyanins (cyanidin, delphinidin, malvidin, pelargonidin, petunidin, peonidin), flavanones (eriodictyol, hesperetin, naringenin), flavan‐3‐ols (catechins, gallocatechins, epicatachin, epigallocatechin, epicatachin‐3‐gallate, epigallocatechin‐3‐gallate), flavonols (quercetin, kaempferol, myricetin, isohamnetin), flavones (luteolin, apigenin), and polymers (including proanthocyanidins excluding monomers, theaflavins, and thearubigins). The measure "total flavonoids" represented the sum of these 6 subclasses. Assessment of daily dietary folic acid intake was based on the frequency and dosage information from the FFQ. The average daily total fruit and total vegetable intake (servings/day) was also measured based on FFQ, over the past year. The estimates were made using software developed by the Nurses\' Health Study at the Channing Laboratories and processed by Channing Laboratories operators. To avoid undue influence of outliers, we excluded all the questionnaires reporting \<500 or \>4200 total calories per day. We also truncated flavonoid and folic acid intakes at median±3×(interquartile range). Fewer than 0.5% of observations were excluded.

Statistical Methods
-------------------

### Confounding selection and model assumption

For the analysis involving PM~2.5~ exposure, *TLR2* methylation, and HRV, we adjusted for potential confounders, selected based on literature evidence (ie, age, room temperature, outdoor apparent temperature, season \[winter/spring--fall/summer\], household income, weekday of the visit, and the visit date). To increase efficiency, we also adjusted for the following risk factors for decreased HRV: body mass index (BMI), smoking status (never/former/current), physical activity, fasting glucose, alcohol consumption (\<2 drinks/d/≥2 drinks/d), hypertension, and use of calcium channel blockers, β‐blockers, and angiotensin‐converting enzyme inhibitors. For the analysis examining flavonoid and methyl nutrients intake as effect modifier(s) for the association between PM~2.5~ exposure and HRV, we adjusted for all the covariates listed above, as well as for total fiber, vitamin C, and caloric intakes. To examine the effect of flavonoid and methyl nutrients intakes on *TLR*2 methylation, we adjusted for age, body mass index, smoking status, total fiber, vitamin C, caloric intake, household income, and physical activity.

HR, rMSSD, SDNN, LF, and HF were log~10~‐transformed to improve normality and stabilize the variance. All independent variables were fitted as time‐varying covariates. Nonlinear relationships were characterized first using graphical analyses between HRV and all the covariates, as well as between nutrient intakes and *TLR*2 methylation. When the graphical analyses suggested nonlinear association, higher‐order terms (quadratic, cubic, etc.) were considered in the model, and a likelihood ratio test was used to determine the number of higher‐order terms needed. In the present study, nonlinearity between apparent temperature and HRV was accounted for by the use of linear and quadratic terms. In addition, we utilized the likelihood ratio test to determine whether it is adequate to model the effect modifiers with a linear trend. Additional analysis using spline regression models were also used to confirm linearity.

To account for repeated assessments for many participants, all statistical models were linear mixed‐effect models with a random intercept assigned to each subject, which used compound symmetry covariance structure. A compound symmetry covariance structure was decided upon after comparing the Akaike information criterion (AIC) among models with different covariance structures as well as assessing the fit of the compound symmetry covariance structure to our data by examining the estimated residual covariance matrix. An analysis using a robust/sandwich estimator for the variance gave very similar results and thus analysis without use of robust/sandwich variance estimators were reported in the manuscript. To examine whether any position in the *TLR*2 promoter region modified the association between PM~2.5~ exposure and HRV, we fitted a single linear mixed‐effect model with 5 interaction terms included in the model, which are the interactions between each of the 5 *TLR2* positions and PM~2.5~ (in addition to their respective main effects and other covariates) (Model 1). To test the null hypothesis that none of the positions modified the association between PM~2.5~ exposure and HRV (H~0~: γ~1~=γ~2~=...=γ~5~=0), the coefficients of these 5 interaction terms were tested all together using a single Wald test, whose null distribution is approximated using an F‐distribution (global test).

As a secondary analysis, we also examined the effect modification by position‐specific *TLR2* methylation by including an interaction term between position‐specific *TLR2* methylation and PM~2.5~ in the model (Model 2), only if the global test was significant.

where Y~ij~ was the log~10~ of HRV measures for participant i at visit j, β~0~ was the overall intercept, b~i~ was the separate random intercept for subject i, and b~i~\~N(0, ϴ),ε~ij~\~N(0, σ^2^). *TLR2*~*kij*~ was the *TLR2* methylation level at the k~th~ position (k=1−5) within the promoter region, for participant i at visit j. X~2ij~--X~pij~ were the covariates including confounders and predictors for HRV, for participant i at visit j.

To describe the effect modification by potential effect modifiers, we estimated from the mixed‐effect models the HRV‐PM~2.5~ associations at the values corresponding to the quartiles of each effect modifier and reported them separately. We reported effect estimates, 95% CIs, and *P* values for the HRV‐PM~2.5~ associations from the linear mixed‐effect models (ie, percent change in HRV per 10 μg/m^3^ increase in PM~2.5~) for the midpoint of each quartile. Analyses were performed using SAS 9.4 (SAS Institute, Cary, NC).

Results
=======

Cohort Characteristics and Exposure Levels
------------------------------------------

The Normative Aging Study is a cohort of aging individuals, between 55 and 100 years old at the first visit of the present study ([Figure 1](#fig01){ref-type="fig"}). We excluded N=91 participants with heart arrhythmias at baseline. An additional N=63 participants were excluded as they had missing outcome (N=13 with missing HRV) or missing exposure (N=50 with missing PM~2.5~ exposure), giving a total of N=573. The baseline characteristics of the participants included in the final analysis are given in [Table 1](#tbl01){ref-type="table"}. All participants were male, and 96% were white. Seventy‐nine percent of the participants were overweight, 19% were diabetics, and 71% were hypertensive. The study population included 5% current smokers and 19% heavy alcohol drinkers (≥2 drinks/d). During the study period (November 2000--December 2011), the 48‐hour PM~2.5~ moving average varied between 2.14 and 42.8 μg/m^3^ with an average exposure level of 10.5 μg/m^3^, which is lower than the U.S. Environmental Protection Agency\'s daily health National Ambient Air Quality Standard for PM~2.5~ (35.0 μg/m^3^). The baseline mean methylation level across 5 CpG positions ([Figure 2](#fig02){ref-type="fig"}) in the *TLR2* promoter region ranged between 0.3%5mC and 7.1%5mC. There was no apparent difference in exposure level or methylation level across different characteristic subgroups ([Table 1](#tbl01){ref-type="table"}).

###### 

Baseline Characteristics of Study Participants (N=573), 48‐Hour Moving Average of PM~2.5~, and Averaged Methylation Across CpG Positions in the Promoter Region of *TLR2* Gene

  Characteristics               N (%)        Mean (SD)    
  ----------------------------- ------------ ------------ ------------
  Age, y                                                  
  55 to 69                      176 (30.7)   11.4 (5.2)   2.9 (1.3)
  70 to 79                      293 (51.1)   11.7 (6.4)   3.1 (1.3)
  80 to 89                      97 (16.9)    10.6 (6.1)   2.9 (1.1)
  \>90                          7 (1.2)      13.0 (5.0)   3.4 (1.0)
  Physical activity, MET‐h/wk                             
  \<12                          371 (64.8)   11.4 (6.3)   2.93 (1.2)
  12 to \<30                    114 (19.9)   11.3 (5.3)   3.14 (1.4)
  ≥30                           88 (15.4)    11.7 (5.5)   3.08 (1.2)
  Alcohol (drinks/d)                                      
  ≥2                            106 (18.5)   11.6 (6.7)   2.9 (1.1)
  \<2                           467 (81.5)   11.4 (5.8)   3.0 (1.2)
  Diabetes                                                
  Yes                           111 (19.4)   11.0 (6.0)   2.9 (1.0)
  No                            462 (80.6)   11.5 (6.0)   3.0 (1.3)
  Race                                                    
  White                         549 (95.8)   11.4 (5.9)   3.0 (1.3)
  Nonwhite                      24 (4.2)     11.6 (7.7)   2.8 (0.9)
  Hypertension                                            
  Yes                           405 (70.7)   11.3 (6.0)   3.0 (1.3)
  No                            168 (29.3)   11.8 (6.0)   2.9 (1.2)
  BMI, kg/m^2^                                            
  \<25                          123 (21.5)   12.4 (6.8)   3.0 (1.2)
  ≥25                           450 (78.5)   11.2 (5.7)   3.0 (1.3)
  Smoking                                                 
  Never                         166 (29.0)   11.7 (6.0)   3.1 (1.4)
  Current                       26 (4.5)     10.9 (3.8)   3.3 (1.1)
  Former                        381 (66.5)   11.4 (6.1)   2.9 (1.2)
  Annual income \>\$60 000                                
  Yes                           272 (47.5)   11.0 (5.4)   3.1 (1.3)
  No                            301 (52.5)   11.8 (6.5)   2.9 (1.2)

BMI indicates body mass index; MET, metabolic equivalent of task; PM~2.5~, particulate matter with aerodynamic diameter \<2.5 μm; *TLR2, Toll‐like receptor 2*.

Main Effect of Air Pollutants on HRV
------------------------------------

Average PM~2.5~ exposure over the 48 hours before the day of each visit was associated with significantly lowered SDNN and LF, marginally lowered rMSSD and HF, and nonsignificantly increased HR. Every 10 μg/m^3^ increase in the 48‐hour PM~2.5~ moving average was associated with 7.74% (95% CI, −1.21% to 15.90%; *P*=0.09), 7.46% (95% CI, 0.99% to 13.50%; *P*=0.02), 14.18% (95% CI, 1.14% to 25.49%; *P*=0.03), and 12.94% (95% CI, −2.36% to 25.96%; *P*=0.09) reductions in rMSSD, SDNN, LF, and HF, respectively ([Table 2](#tbl02){ref-type="table"}). Exposure to black carbon, carbon monoxide, nitrogen dioxide, and ozone over the 48 hours before the day of each visit was not significantly associated with HR, rMSSD, SDNN, LF, and HF ([Table 3](#tbl03){ref-type="table"}).

###### 

Effect of 48‐Hour Moving Average of PM~2.5~ on HRV, Normative Aging Study, 2000--2011 (N=500)

  HRV Measure   Change in HRV Per 10 μg/m^3^ Increase in PM~2.5~ Concentration[\*](#tf2-1){ref-type="table-fn"}                     
  ------------- ------------------------------------------------------------------------------------------------- ----------------- ------
  HR            0.42                                                                                              −0.94 to 1.80     0.55
  rMSSD         −7.74                                                                                             −15.90 to 1.21    0.09
  SDNN          −7.46                                                                                             −13.50 to −0.99   0.02
  LF            −14.18                                                                                            −25.49 to −1.14   0.03
  HF            −12.94                                                                                            −25.96 to 2.36    0.09

HF indicates high‐frequency power (0.15 to 0.4 Hz); HR, heart rate; HRV, heart rate variability; LF, low‐frequency power (0.04 to 0.15 Hz); PM~2.5~, particulate matter with aerodynamic diameter \<2.5 μm; rMSSD, root mean square of successive differences; SDNN, standard deviation of normal‐to‐normal intervals.

Results were adjusted for age; body mass index; fasting glucose level; hypertension; smoking status; alcohol consumption; physical exercise; household income; the use of calcium channel blocker, β‐blocker, and angiotensin‐converting enzyme inhibitor; room temperature; outdoor apparent temperature; season; weekday; and visit date.

###### 

Effect of 48‐Hour Moving Average of Black Carbon, Carbon Monoxide, Nitrogen Dioxide, and Ozone on HRV, Normative Aging Study, 2000--2011 (N=573)

  HRV     Black Carbon   Carbon Monoxide   Nitrogen Dioxide   Ozone                                                                                      
  ------- -------------- ----------------- ------------------ ------- ----------------- ------ ------- ---------------- ------ ------- ----------------- ------
  HR      0.04           −0.82 to 0.92     0.92               −0.97   −3.16 to 1.28     0.40   0.25    −0.76 to 1.27    0.63   −0.92   −2.19 to 0.37     0.16
  rMSSD   −2.02          −7.59 to 3.88     0.49               −1.86   −15.63 to 14.15   0.81   −3.71   −10.08 to 3.11   0.28   −5.31   −13.2 to 3.3      0.22
  SDNN    −2.28          −6.36 to 1.98     0.29               −2.19   −12.42 to 9.23    0.69   −1.93   −6.72 to 3.1     0.44   −4.13   −10.04 to 2.17    0.19
  LF      −2.46          −10.82 to 6.68    0.59               −1.61   −21.91 to 23.96   0.89   −1.55   −11.31 to 9.3    0.77   −5.92   −17.66 to 7.5     0.37
  HF      −1.91          −11.45 to 8.67    0.71               −2.55   −25.13 to 26.86   0.85   −7.29   −17.7 to 4.44    0.21   −5.19   −18.57 to 10.39   0.49

HF indicates high‐frequency power (0.15 to 0.4 Hz); HR, heart rate; HRV, heart rate variability; LF, low‐frequency power (0.04 to 0.15 Hz); rMSSD, root mean square of successive differences; SDNN, standard deviation of normal‐to‐normal intervals.

Results were adjusted for age; body mass index; fasting glucose level; hypertension; smoking status; alcohol consumption; physical exercise; household income; the use of calcium channel blocker, β‐blocker, and angiotensin‐converting enzyme inhibitor; room temperature; outdoor apparent temperature; season; weekday; and visit date.

Modification of PM~2.5~ Effect on HRV by *TLR2* Methylation
-----------------------------------------------------------

The effect of 48‐hour PM~2.5~ exposure at participants\' homes on rMSSD, SDNN, LF, and HF was significantly modified by the level of methylation within the *TLR2* promoter region (*P*=0.006 for rMSSD; *P*=0.03 for SDNN; *P*=0.05 for LF; and *P*=0.04 for HF; global test for interaction across 5 positions) ([Table 4](#tbl04){ref-type="table"}). PM~2.5~ exposure had no significant effect on HRV in individuals with low *TLR2* methylation, but it showed increasingly negative effects on HRV as *TLR2* methylation increased ([Figure 3](#fig03){ref-type="fig"}). For instance, in individuals with *TLR2* methylation within the first quartile, every 10 μg/m^3^ increase in 48‐hour PM~2.5~ exposure was associated with 8.77% (95% CI, −7.55% to 27.95%; *P*=0.31), −0.39% (95% CI, −11.76% to 12.45%; *P*=0.95), −7.25% (95% CI, −27.74% to 19.06%; *P*=0.56), and 10.06% (95% CI, −16.25% to 44.64%; *P*=0.49) nonsignificant estimated changes in rMSSD, SDNN, LF, and HF, respectively (effects estimated at the midpoint of the first quartile, ie, 1.5%5mC to represent the within‐quartile effect; [Table 4](#tbl04){ref-type="table"}); on the other hand, in the fourth *TLR2* methylation quartile, every 10 μg/m^3^ increase in 48‐hour PM~2.5~ exposure was associated with 26.38% (95% CI, 13.69% to 37.20%; *P*=0.0002), 13.94% (95% CI, 3.12% to 23.55%; *P*=0.01), 21.40% (95% CI, −0.39% to 38.47%; *P*=0.05), and 34.28% (95% CI, 13.84% to 49.87%; *P*=0.003) reductions in rMSSD, SDNN, LF, and HF, respectively (effects estimated at the midpoint of the fourth quartile, ie, 4.4%5mC to represent the within‐quartile effect). Analysis of individual position‐specific methylation showed notable effect heterogeneity across the 5 CpG positions, with stronger effect modifications by positions 1, 3, and 5 ([Table 5](#tbl05){ref-type="table"}).

###### 

Effect of PM~2.5~ Exposure on HRV at Different Mean *TLR2* Methylation Levels, Normative Aging Study, 2000--2011 (N=500)

  Mean *TLR2* Methylation                                        \% Change[\*](#tf4-1){ref-type="table-fn"}   95% CI             *P* Value
  -------------------------------------------------------------- -------------------------------------------- ------------------ -----------
  HR                                                                                                                             
  Midpoint of Q1 (1.5 5mc%)                                      −0.56                                        −2.88 to 1.82      0.64
  Midpoint of Q2 (2.2 5mc%)                                      −0.10                                        −1.99 to 1.81      0.92
  Midpoint of Q3 (3.0 5mc%)                                      0.42                                         −1.25 to 2.11      0.62
  Midpoint of Q4 (4.4 5mc%)                                      1.34                                         −0.92 to 3.66      0.25
  *P*~global~ for interaction[\*](#tf4-2){ref-type="table-fn"}                                                                   0.62
  rMSSD                                                                                                                          
  Midpoint of Q1 (1.5 5mc%)                                      8.77                                         −7.55 to 27.95     0.31
  Midpoint of Q2 (2.2 5mc%)                                      −1.01                                        −13.14 to 12.81    0.88
  Midpoint of Q3 (3.0 5mc%)                                      −11.11                                       −20.87 to −0.16    0.05
  Midpoint of Q4 (4.4 5mc%)                                      −26.38                                       −37.20 to −13.69   0.0002
  *P*~global~ for interaction[\*](#tf4-2){ref-type="table-fn"}                                                                   0.006
  SDNN                                                                                                                           
  Midpoint of Q1 (1.5 5mc%)                                      −0.39                                        −11.76 to 12.45    0.95
  Midpoint of Q2 (2.2 5mc%)                                      −3.85                                        −12.78 to 6.00     0.43
  Midpoint of Q3 (3.0 5mc%)                                      −7.65                                        −15.31 to 0.71     0.07
  Midpoint of Q4 (4.4 5mc%)                                      −13.94                                       −23.55 to −3.12    0.01
  *P*~global~ for interaction[\*](#tf4-2){ref-type="table-fn"}                                                                   0.03
  LF                                                                                                                             
  Midpoint of Q1 (1.5 5mc%)                                      −7.25                                        −27.74 to 19.06    0.56
  Midpoint of Q2 (2.2 5mc%)                                      −10.88                                       −27.11 to 8.96     0.26
  Midpoint of Q3 (3.0 5mc%)                                      −14.86                                       −28.80 to 1.81     0.08
  Midpoint of Q4 (4.4 5mc%)                                      −21.40                                       −38.47 to 0.39     0.05
  *P*~global~ for interaction[\*](#tf4-2){ref-type="table-fn"}                                                                   0.05
  HF                                                                                                                             
  Midpoint of Q1 (1.5 5mc%)                                      10.06                                        −16.25 to 44.64    0.49
  Midpoint of Q2 (2.2 5mc%)                                      −2.82                                        −22.02 to 21.10    0.80
  Midpoint of Q3 (3.0 5mc%)                                      −15.71                                       −30.75 to 2.60     0.09
  Midpoint of Q4 (4.4 5mc%)                                      −34.28                                       −49.87 to −13.84   0.003
  *P*~global~ for interaction[\*](#tf4-2){ref-type="table-fn"}                                                                   0.04

Results were adjusted for age; body mass index; fasting glucose level; hypertension; smoking status; alcohol consumption; physical exercise; household income; the use of calcium channel blocker, β‐blocker, and angiotensin‐converting enzyme inhibitor; room temperature; outdoor apparent temperature; season; weekday; and visit date. Q1, Q2, Q3, and Q4 indicate the first, second, third, and fourth quartile. HF indicates high‐frequency power (0.15 to 0.4 Hz); HR, heart rate; HRV, heart rate variability; LF, low‐frequency power (0.04 to 0.15 Hz); PM~2.5~, particulate matter with aerodynamic diameter \<2.5 μm; rMSSD, root mean square of successive differences; SDNN, standard deviation of normal‐to‐normal intervals; *TLR2*,*Toll‐like receptor 2*.

The percent change in HRV per 10 μg/m^3^ increase in PM~2.5~ concentration.

Based on a global test for effect modification by position‐specific methylation. Interaction terms between each of the 5 *TLR2* positions and PM~2.5~ were included in the model, and these 5 interaction terms were tested jointly for effect modification using a Wald test (global test).

###### 

Effect Modification by Position‐Specific *TLR2* Methylation on the Association Between PM~2.5~ Exposure and HRV (N=500)

  Position                                               Methylation      \% Change[\*](#tf5-1){ref-type="table-fn"}   95% CI            *P* Value   \% Change[\*](#tf5-1){ref-type="table-fn"}   95% CI            *P* Value   \% Change[\*](#tf5-1){ref-type="table-fn"}   95% CI            *P* Value
  ------------------------------------------------------ ---------------- -------------------------------------------- ----------------- ----------- -------------------------------------------- ----------------- ----------- -------------------------------------------- ----------------- -----------
                                                                          HR                                           rMSSD             SDNN                                                                                                                                                  
  1                                                      Midpoint of Q1   0.36                                         −1.96 to 2.75     0.76        7.26                                         −8.65 to 25.94    0.39        1.66                                         −9.79 to 14.56    0.79
  Midpoint of Q2                                         0.42             −1.38 to 2.24                                0.65              −4.56       −15.66 to 8.01                               0.46              −4.30       −12.71 to 4.93                               0.35              
  Midpoint of Q3                                         0.46             −1.22 to 2.17                                0.60              −13.25      −22.84 to −2.47                              0.02              −8.91       −16.51 to −0.63                              0.04              
  Midpoint of Q4                                         0.53             −1.72 to 2.83                                0.65              −26.01      −36.84 to −13.31                             0.0002            −16.11      −25.42 to −5.64                              0.004             
  *P* for interaction[\*](#tf5-2){ref-type="table-fn"}                                                                 0.92                                                                       0.0009                                                                     0.02              
  2                                                      Midpoint of Q1   0.08                                         −2.12 to 2.34     0.94        −0.21                                        −14.47 to 16.43   0.98        −7.00                                        −17.08 to 4.3     0.22
  Midpoint of Q2                                         0.28             −1.49 to 2.09                                0.76              −6.61       −17.49 to 5.72                               0.28              −7.36       −15.51 to 1.58                               0.10              
  Midpoint of Q3                                         0.44             −1.23 to 2.13                                0.61              −11.33      −21.1 to −0.35                               0.04              −7.64       −15.31 to 0.73                               0.07              
  Midpoint of Q4                                         0.75             −1.4 to 2.95                                 0.50              −20.06      −31.31 to −6.98                              0.004             −8.20       −17.98 to 2.74                               0.14              
  *P* for interaction[\*](#tf5-2){ref-type="table-fn"}                                                                 0.65                                                                       0.03                                                                       0.86              
  3                                                      Midpoint of Q1   −0.82                                        −3.19 to 1.61     0.51        5.96                                         −10.3 to 25.17    0.50        1.15                                         −10.63 to 14.49   0.86
  Midpoint of Q2                                         −0.16            −1.99 to 1.71                                0.86              −3.69       −15.24 to 9.44                               0.56              −3.72       −12.44 to 5.87                               0.43              
  Midpoint of Q3                                         0.37             −1.3 to 2.07                                 0.67              −10.77      −20.6 to 0.28                                0.06              −7.44       −15.13 to 0.94                               0.08              
  Midpoint of Q4                                         1.27             −0.85 to 3.44                                0.24              −21.64      −32.48 to −9.05                              0.00              −13.45      −22.51 to −3.33                              0.01              
  *P* for interaction[\*](#tf5-2){ref-type="table-fn"}                                                                 0.18                                                                       0.005                                                                      0.05              
  4                                                      Midpoint of Q1   −0.28                                        −2.62 to 2.12     0.82        2.48                                         −12.89 to 20.56   0.77        −4.43                                        −15.3 to 7.83     0.46
  Midpoint of Q2                                         0.11             −1.73 to 1.99                                0.90              −4.88       −16.33 to 8.13                               0.44              −6.13       −14.66 to 3.25                               0.19              
  Midpoint of Q3                                         0.45             −1.22 to 2.15                                0.60              −10.81      −20.64 to 0.23                               0.06              −7.57       −15.25 to 0.8                                0.08              
  Midpoint of Q4                                         1.10             −1.08 to 3.32                                0.33              −21.06      −32.16 to −8.15                              0.002             −10.25      −19.8 to 0.45                                0.06              
  *P* for interaction[\*](#tf5-2){ref-type="table-fn"}                                                                 0.38                                                                       0.01                                                                       0.43              
  5                                                      Midpoint of Q1   −1.24                                        −3.63 to 1.2      0.32        6.37                                         −9.99 to 25.69    0.47        1.72                                         −10.17 to 15.19   0.79
  Midpoint of Q2                                         −0.31            −2.15 to 1.57                                0.75              −3.71       −15.29 to 9.45                               0.56              −3.62       −12.39 to 6.02                               0.45              
  Midpoint of Q3                                         0.48             −1.2 to 2.18                                 0.58              −11.31      −21.05 to −0.36                              0.04              −7.82       −15.46 to 0.52                               0.07              
  Midpoint of Q4                                         1.81             −0.34 to 4                                   0.10              −22.79      −33.47 to −10.39                             0.0007            −14.49      −23.45 to −4.47                              0.006             
  *P* for interaction[\*](#tf5-2){ref-type="table-fn"}                                                                 0.05                                                                       0.003                                                                      0.03              
                                                                          LF                                           HF                                                                                                                                                                      
  1                                                      Midpoint of Q1   −11.35                                       −30.67 to 13.36   0.34        1.00                                         −22.87 to 32.27   0.94                                                                       
  Midpoint of Q2                                         −13.74           −28.64 to 4.28                               0.13              −9.74       −26.73 to 11.19                              0.34                                                                                         
  Midpoint of Q3                                         −15.64           −29.53 to 0.98                               0.06              −17.68      −32.53 to 0.45                               0.06                                                                                         
  Midpoint of Q4                                         −18.73           −36.26 to 3.64                               0.10              −29.38      −46.1 to −7.48                               0.01                                                                                         
  *P* for interaction[\*](#tf5-2){ref-type="table-fn"}                                                                 0.61                                                                       0.06                                                                                         
  2                                                      Midpoint of Q1   −17.70                                       −34.99 to 4.19    0.11        −5.94                                        −27.43 to 21.91   0.64                                                                       
  Midpoint of Q2                                         −16.04           −30.54 to 1.48                               0.07              −11.67      −28.3 to 8.83                                0.24                                                                                         
  Midpoint of Q3                                         −14.72           −28.69 to 1.99                               0.08              −15.90      −30.99 to 2.48                               0.09                                                                                         
  Midpoint of Q4                                         −12.02           −30.33 to 11.11                              0.28              −23.77      −41.18 to −1.22                              0.04                                                                                         
  *P* for interaction[\*](#tf5-2){ref-type="table-fn"}                                                                 0.67                                                                       0.22                                                                                         
  3                                                      Midpoint of Q1   4.93                                         −18.73 to 35.46   0.71        10.57                                        −16.54 to 46.49   0.48                                                                       
  Midpoint of Q2                                         −6.44            −23.08 to 13.79                              0.51              −4.44       −22.97 to 18.55                              0.68                                                                                         
  Midpoint of Q3                                         −14.64           −28.62 to 2.06                               0.08              −14.96      −30.18 to 3.58                               0.11                                                                                         
  Midpoint of Q4                                         −26.97           −41.87 to −8.26                              0.007             −30.26      −45.83 to −10.2                              0.005                                                                                        
  *P* for interaction[\*](#tf5-2){ref-type="table-fn"}                                                                 0.03                                                                       0.01                                                                                         
  4                                                      Midpoint of Q1   −12.69                                       −31.92 to 11.98   0.29        −0.15                                        −24.04 to 31.25   0.99                                                                       
  Midpoint of Q2                                         −13.86           −29.23 to 4.84                               0.14              −8.49       −26.31 to 13.62                              0.42                                                                                         
  Midpoint of Q3                                         −14.86           −28.79 to 1.8                                0.08              −15.14      −30.32 to 3.36                               0.10                                                                                         
  Midpoint of Q4                                         −16.72           −33.93 to 4.96                               0.12              −26.43      −42.95 to −5.13                              0.02                                                                                         
  *P* for interaction[\*](#tf5-2){ref-type="table-fn"}                                                                 0.77                                                                       0.09                                                                                         
  5                                                      Midpoint of Q1   −1.26                                        −23.57 to 27.57   0.92        15.29                                        −12.68 to 52.22   0.32                                                                       
  Midpoint of Q2                                         −9.27            −25.47 to 10.46                              0.33              −3.32       −21.96 to 19.78                              0.76                                                                                         
  Midpoint of Q3                                         −15.39           −29.24 to 1.17                               0.07              −16.41      −31.27 to 1.68                               0.07                                                                                         
  Midpoint of Q4                                         −24.79           −40.16 to −5.46                              0.01              −34.57      −49.1 to −15.88                              0.001                                                                                        
  *P* for interaction[\*](#tf5-2){ref-type="table-fn"}                                                                 0.10                                                                       0.002                                                                                        

HF indicates high‐frequency power (0.15 to 0.4 Hz); HR, heart rate; HRV, heart rate variability; LF, low‐frequency power (0.04 to 0.15 Hz); PM~2.5~, particulate matter with aerodynamic diameter \<2.5 μm; Q1, Q2, Q3, and Q4 indicate the first, second, third, and fourth quartile; rMSSD, root mean square of successive differences; SDNN, standard deviation of normal‐to‐normal intervals; *TLR2*,*Toll‐like receptor 2*.

The percent change in HRV per 10 μg/m^3^ increase in PM~2.5~ concentration. Results were adjusted for age; body mass index; fasting glucose level; hypertension; smoking status; alcohol consumption; physical exercise; household income; the use of calcium channel blocker, β‐blocker, and angiotensin‐converting enzyme inhibitor; room temperature; outdoor apparent temperature; season; weekday; and visit date.

To examine effect modification by position‐specific *TLR2* methylation, an interaction term between position‐specific *TLR2* methylation and PM~2.5~ was included in the model.

![The effect of particulate matter with aerodynamic diameter \<2.5 μm (PM~2.5~) exposure on heart rate variability (HRV) at different mean *Toll‐like receptor 2* (*TLR2*) methylation levels, Normative Aging Study, 2000--2011 (N=500). log~10~HR indicates log~10~‐transformed heart rate; log~10~rMSSD, log~10~‐transformed root mean square of the successive differences; log~10~SDNN, log~10~‐transformed standard deviation of normal‐to‐normal intervals; log~10~LF, log~10~‐transformed low‐frequency power (0.04 to 0.15 Hz); log~10~HF, log~10~‐transformed high‐frequency power (0.15 to 0.4 Hz); Q1, Q2, Q3, and Q4 indicate the first, second, third, and fourth quartiles. The association of PM~2.5~ with rMSSD, SDNN, LF, and HF is modified by mean *TLR2* methylation levels, as indicated by the different slopes. The 4 lines in each figure represent the relationship between PM~2.5~ and HRV when the mean *TLR2* methylation level is at the midpoints of each quartile. If there was no effect modification, the 4 lines would be the same. The *P*~global~ for interaction was based on a global test for effect modification by position‐specific methylation. Interaction terms between each of the 5 *TLR2* positions and PM~2.5~ were included in the model, and these 5 interaction terms were tested jointly for effect modification using a Wald test (global test). Results were adjusted for age; body mass index; fasting glucose level; hypertension; smoking status; alcohol consumption; physical exercise; household income; the use of calcium channel blocker, β‐blocker, and angiotensin‐converting enzyme inhibitor; room temperature; outdoor apparent temperature; season; weekday; and visit date.](jah3-4-e001423-g3){#fig03}

Association of Flavonoid and Methyl Nutrients Intakes With *TLR*2 methylation
-----------------------------------------------------------------------------

The average daily flavonoid intake over the preceding year was negatively associated with mean *TLR2* methylation, considered as the average methylation level across 5 CpG positions (5.09% reduction; 95% CI, 0.12% to 10.06%; per an interquartile‐range increase in flavonoid intake; *P*=0.05) ([Figure 4](#fig04){ref-type="fig"}). In position‐specific analyses ([Figure 4](#fig04){ref-type="fig"} and [Table 6](#tbl06){ref-type="table"}), methylation at *TLR2* promoter positions 1 and 4 showed the strongest associations with flavonoid intake. We did not observe significant association between methyl nutrients (folic acid, vitamin B12, and methionine) intakes in the previous year and either mean or position‐specific *TLR2* methylation (Figures [4](#fig04){ref-type="fig"} and [5](#fig05){ref-type="fig"}).

###### 

Effect of Dietary Flavonoid Intake on Mean and Position‐Specific *TLR2* Methylation, Adjusted for Total Fruit and Vegetable Intake

               Original Model (N=497)[\*](#tf6-1){ref-type="table-fn"}   Adjusted for Total Fruit and Vegetable Intake (N=482)[\*](#tf6-2){ref-type="table-fn"}                                      
  ------------ --------------------------------------------------------- ---------------------------------------------------------------------------------------- -------- ------- ----------------- ------
  Position 1   −10.02                                                    −17.37 to −2.66                                                                          \<0.01   −8.47   −15.94 to −1.01   0.03
  Position 2   −3.81                                                     −10.31 to 2.69                                                                           0.25     −2.51   −9.33 to 4.30     0.48
  Position 3   −4.49                                                     −12.11 to 3.14                                                                           0.25     −4.28   −12.11 to 3.55    0.28
  Position 4   −6.05                                                     −12.74 to 0.65                                                                           0.08     −6.61   −13.51 to 0.29    0.06
  Position 5   −3.31                                                     −14.26 to 7.64                                                                           0.55     −4.82   −16.12 to 6.48    0.41
  Mean         −5.09                                                     −10.06 to −0.12                                                                          0.05     −4.99   −10.16 to 0.17    0.06

*TLR2* indicates *Toll‐like receptor 2*.

Results were adjusted for age, year of visit, body mass index, total caloric intake, total vitamin C intake, total fiber intake, smoking status, household income, and physical activity.

In addition to all the covariates in the original model except total vitamin C and fiber intake, results were adjusted for total fruit and vegetable intake.

![Effect of dietary flavonoid (N=497) and folic acid (N=482) intake on mean and position‐specific *Toll‐like receptor 2* (*TLR2*) methylation. IQR indicates interquartile range. Results were adjusted for age, body mass index, total caloric intake, total vitamin C intake, total fiber intake, smoking status, household income, and physical activity.](jah3-4-e001423-g4){#fig04}

![Effect of dietary vitamin B12 (N=497) and methionine (N=482) intake on mean and position‐specific *Toll‐like receptor 2* (*TLR2*) methylation. IQR indicates interquartile range. Results were adjusted for age, body mass index, total caloric intake, total vitamin C intake, total fiber intake, smoking status, household income, and physical activity.](jah3-4-e001423-g5){#fig05}

Effect Modification by Flavonoid and Methyl Nutrients Intakes
-------------------------------------------------------------

Higher average daily flavonoid intake over the preceding year significantly weakened the association between PM~2.5~ exposure and LF reduction (*P*=0.05), and produced a nonsignificant attenuation of the effect of PM~2.5~ exposure on rMSSD, SDNN, and HF (*P*=0.79 for rMSSD; *P*=0.37 for SDNN; *P*=0.28 for HF) ([Table 7](#tbl07){ref-type="table"} and [Figure 6](#fig06){ref-type="fig"}). PM~2.5~ exposure had no significant effect on LF in individuals with high flavonoid intake, but it was associated with increasingly negative effects on LF as flavonoid intakes decreased ([Figure 6](#fig06){ref-type="fig"}). In particular, in individuals at the first quartile of flavonoid intake, every 10 μg/m^3^ increase in 48‐hour PM~2.5~ exposure was associated with a 16.48% (95% CI, −1.61% to 31.35%; *P*=0.07) reduction in LF (effects estimated at the midpoint of the first quartile, ie, 128 mg/d to represent the within‐quartile effect), while no effect was seen for the second, third, and fourth flavonoid quartile ([Table 7](#tbl07){ref-type="table"}). The effect modification by flavonoid intake was abrogated when mean *TLR2* methylation and the interaction between mean *TLR2* methylation and PM~2.5~ exposure were fitted in the model ([Table 8](#tbl08){ref-type="table"}).

###### 

Effect of PM~2.5~ Exposure on HRV at Different Daily Flavonoid Intake Levels, Normative Aging Study, 2000--2011 (N=513)

  Flavonoid Intake            \% Change[\*](#tf7-1){ref-type="table-fn"}   95% CI            *P* Value
  --------------------------- -------------------------------------------- ----------------- -----------
  HR                                                                                         
  Midpoint of Q1 (128 mg/d)   0.06                                         −1.65 to 1.80     0.95
  Midpoint of Q2 (228 mg/d)   0.00                                         −1.51 to 1.53     1.00
  Midpoint of Q3 (370 mg/d)   −0.09                                        −1.45 to 1.30     0.90
  Midpoint of Q4 (673 mg/d)   −0.26                                        −1.98 to 1.48     0.76
  *P* for interaction                                                                        0.76
  rMSSD                                                                                      
  Midpoint of Q1 (128 mg/d)   −5.32                                        −16.91 to 7.88    0.41
  Midpoint of Q2 (228 mg/d)   −4.94                                        −15.25 to 6.62    0.39
  Midpoint of Q3 (370 mg/d)   −4.41                                        −13.82 to 6.03    0.39
  Midpoint of Q4 (673 mg/d)   −3.25                                        −15.28 to 10.49   0.63
  *P* for interaction                                                                        0.79
  SDNN                                                                                       
  Midpoint of Q1 (128 mg/d)   −6.14                                        −14.57 to 3.11    0.19
  Midpoint of Q2 (228 mg/d)   −5.22                                        −12.74 to 2.95    0.20
  Midpoint of Q3 (370 mg/d)   −3.89                                        −10.81 to 3.56    0.30
  Midpoint of Q4 (673 mg/d)   −1.00                                        −10.03 to 8.93    0.84
  *P* for interaction                                                                        0.37
  LF                                                                                         
  Midpoint of Q1 (128 mg/d)   −16.48                                       −31.35 to 1.61    0.07
  Midpoint of Q2 (228 mg/d)   −12.55                                       −26.37 to 3.87    0.13
  Midpoint of Q3 (370 mg/d)   −6.65                                        −20.07 to 9.03    0.39
  Midpoint of Q4 (673 mg/d)   7.31                                         −12.16 to 31.11   0.49
  *P* for interaction                                                                        0.05
  HF                                                                                         
  Midpoint of Q1 (128 mg/d)   −10.42                                       −28.69 to 12.54   0.34
  Midpoint of Q2 (228 mg/d)   −7.78                                        −24.49 to 12.63   0.43
  Midpoint of Q3 (370 mg/d)   −3.89                                        −19.74 to 15.09   0.67
  Midpoint of Q4 (673 mg/d)   4.96                                         −16.93 to 32.63   0.68
  *P* for interaction                                                                        0.28

Results were adjusted for age; body mass index; total caloric intake; total vitamin C intake; total fiber intake; fasting glucose level; hypertension; smoking status; alcohol consumption; physical exercise; household income; the use of calcium channel blocker, β‐blocker, and angiotensin‐converting enzyme inhibitor; room temperature; outdoor apparent temperature; season; weekday; and visit date. HF indicates high‐frequency power (0.15 to 0.4 Hz); HR, heart rate; HRV, heart rate variability; LF, low‐frequency power (0.04 to 0.15 Hz); PM~2.5~, particulate matter with aerodynamic diameter \<2.5 μm; Q1, Q2, Q3, and Q4 indicate the first, second, third, and fourth quartile; rMSSD, root mean square of successive differences; SDNN, standard deviation of normal‐to‐normal intervals.

The percent change in HRV per 10 μg/m^3^ increase in PM~2.5~ concentration.

###### 

Effect Modification by Flavonoid Intake on the Association Between PM~2.5~ Exposure and HRV, Adjusted for Total Fruit and Vegetable Intake, and Adjusted for Mean *TLR2* Methylation

  HRV Measure   Original Model (N=513)[\*](#tf8-1){ref-type="table-fn"}   Adjusted for Total Fruit and Vegetable Intake (N=482)[\*](#tf8-2){ref-type="table-fn"}   Adjusted for Mean *TLR2* Methylation (N=423)[\*](#tf8-3){ref-type="table-fn"}                                                             
  ------------- --------------------------------------------------------- ---------------------------------------------------------------------------------------- ------------------------------------------------------------------------------- ------- ---------------- ------ ------- ----------------- ------
  HR            −0.18                                                     −1.32 to 0.98                                                                            0.76                                                                            −0.30   −1.48 to 0.90    0.62   0.89    −0.72 to 2.52     0.30
  rMSSD         1.17                                                      −7.38 to 10.51                                                                           0.79                                                                            0.67    −8.45 to 10.7    0.89   0.07    −11.28 to 12.87   0.99
  SDNN          2.98                                                      −3.43 to 9.81                                                                            0.37                                                                            2.77    −3.88 to 9.88    0.42   2.28    −6.49 to 11.87    0.62
  LF            14.63                                                     0.27 to 31.03                                                                            0.05                                                                            15.81   0.50 to 33.45    0.04   10.48   −8.39 to 33.24    0.30
  HF            8.98                                                      −6.93 to 27.62                                                                           0.28                                                                            7.65    −9.17 to 27.59   0.40   7.65    −12.28 to 32.10   0.48

HF indicates high‐frequency power (0.15 to 0.4 Hz); HR, heart rate; HRV, heart rate variability; LF, low‐frequency power (0.04 to 0.15 Hz); PM~2.5~, particulate matter with aerodynamic diameter \<2.5 μm; rMSSD, root mean square of successive differences; SDNN, standard deviation of normal‐to‐normal intervals; *TLR2*,*Toll‐like receptor 2*.

Results were adjusted for age; body mass index; total caloric intake; total vitamin C intake; total fiber intake; fasting glucose level; hypertension; smoking status; alcohol consumption; physical exercise; household income; the use of calcium channel blocker, β‐blocker, and angiotensin‐converting enzyme inhibitor; room temperature; outdoor apparent temperature; season; weekday, and visit date.

In addition to all the covariates in the original model except total vitamin C and fiber intake, results were adjusted for total fruit and vegetable intake.

In addition to all the covariates in the original model, results were adjusted for mean *TLR2* methylation, and the interaction between mean *TLR2* methylation and PM~2.5~ concentration.

The additional percent change in HRV associated with 10 μg/m^3^ PM~2.5~ concentration, compared to participants with 1 interquartile range lower flavonoid intake level.

![The effect of particulate matter with aerodynamic diameter \<2.5 μm (PM~2.5~) exposure on heart rate variability (HRV) at different flavonoid intake levels, Normative Aging Study, 2000--2011 (N=513). log~10~HR indicates log~10~‐transformed heart rate; log~10~rMSSD, log~10~‐transformed root mean square of the successive differences; log~10~SDNN, log~10~‐transformed standard deviation of normal‐to‐normal intervals; log~10~LF, log~10~‐transformed low‐frequency power (0.04 to 0.15 Hz); log~10~HF, log~10~‐transformed high‐frequency power (0.15 to 0.4 Hz); Q1, Q2, Q3, and Q4 indicate the first, second, third, and fourth quartiles. The association of PM~2.5~ on rMSSD, SDNN, LF, and HF is modified by flavonoid intake, as indicated by the different slopes. The 4 lines in each figure represent the relationship between PM~2.5~ and HRV when the flavonoid intake is at the midpoints of each quartile. If there was no effect modification, the 4 lines would be the same. Results were adjusted for age; body mass index; total caloric intake; total vitamin C intake; total fiber intake; fasting glucose level; hypertension; smoking status; alcohol consumption; physical exercise; household income; the use of calcium channel blocker, β‐blocker, and angiotensin‐converting enzyme inhibitor; room temperature; outdoor apparent temperature; season; weekday; and visit date.](jah3-4-e001423-g6){#fig06}

Correlation of Plasma Inflammatory Markers With *TLR*2 Methylation
------------------------------------------------------------------

Increased *TLR2* methylation level was consistently correlated with increased plasma intercellular adhesion molecule 1 level, across 5 CpG positions (*P*\<0.0001, *P*\<0.0001, *P*=0.0002, *P*=0.0004, and *P*=0.0003, respectively) ([Table 9](#tbl09){ref-type="table"}). IL‐8 and vascular endothelial growth factor were also positively correlated with *TLR2* methylation level at position 3 (*P*=0.01, *P*=0.02, respectively) ([Table 9](#tbl09){ref-type="table"}).

###### 

Correlation Between Mean Blood *TLR2* Methylation and Plasma Inflammatory Markers

           *TLR2* Methylation                                                                               
  -------- -------------------- ---------- -------- ---------- -------- -------- -------- -------- -------- --------
  IL‐6     −0.067               0.08       −0.025   0.52       0.067    0.08     0.040    0.30     0.020    0.60
  IL‐8     −0.004               0.93       0.006    0.88       0.095    0.01     0.053    0.17     0.049    0.20
  IL‐1β    −0.031               0.42       0.040    0.31       0.046    0.23     0.019    0.63     0.015    0.70
  TNF‐α    −0.043               0.27       −0.056   0.15       0.006    0.87     −0.009   0.81     −0.039   0.32
  TNFγ     −0.030               0.44       −0.007   0.86       −0.017   0.66     −0.029   0.45     −0.022   0.58
  CRP      0.032                0.35       −0.007   0.85       0.011    0.76     0.024    0.49     0.047    0.17
  ICAM‐1   0.138                \<0.0001   0.159    \<0.0001   0.127    0.0002   0.123    0.0004   0.124    0.0003
  VEGF     −0.022               0.57       −0.016   0.68       0.091    0.02     0.050    0.20     0.046    0.24

CRP indicates C‐reactive protein; ICAM‐1, intercellular adhesion molecule 1; IL, interleukin; *TLR2*,*Toll‐like receptor 2*; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor.

*P* value represents Prob\>\|r\| under H~0~: ρ (Spearman\'s rank correlation coefficient)=0.

Sensitivity Analyses
--------------------

The major sources of dietary flavonoids and folic acid are fruits and vegetables, which contain other nutrients that are likely to affect DNA methylation. Therefore, in sensitivity analysis of models including flavonoids, we adjusted for daily total fruit and vegetable intake---instead of total vitamin C and fiber intake---to examine the robustness of our findings. This adjustment only resulted in minor changes in the effect estimates for the association between flavonoid and *TLR2* methylation, as well as of the effect modification by flavonoid of the effect of PM~2.5~ exposure on HRV (Tables [6](#tbl06){ref-type="table"} and [8](#tbl08){ref-type="table"}).

Due to the high tissue and cell‐type specificity of DNA methylation, DNA methylation in whole blood might be affected by differences in the proportions of leukocyte cell types.^[@b36]^ We therefore examined the correlation between the percentage of specific leukocyte types (ie, eosinophils, lymphocytes, neutrophils, monocytes, and basophils) and *TLR2* methylation level. Among these 5 leukocyte types, the percentage of lymphocytes and neutrophils in total blood cells were correlated with *TLR2* methylation ([Table 10](#tbl10){ref-type="table"}). Therefore, we performed sensitivity analysis adjusted for lymphocyte and neutrophil percentages. Our findings were not affected by this adjustment ([Table 11](#tbl11){ref-type="table"}).

###### 

Correlation Between Mean Blood *TLR2* Methylation Level and Proportions of Different Leukocyte Cell Types

  Cell Type (%)   Spearman Correlation With Mean *TLR2* Methylation[\*](#tf10-1){ref-type="table-fn"}   
  --------------- ------------------------------------------------------------------------------------- -------
  Eosinophils     0.051                                                                                 0.145
  Lymphocytes     0.121                                                                                 0.001
  Neutrophils     −0.118                                                                                0.001
  Monocytes       0.018                                                                                 0.604
  Basophils       0.012                                                                                 0.730

*TLR2* indicates *Toll‐like receptor 2*.

Mean *TLR2* methylation level across 5 CpG sites.

*P* value represents Prob\>\|r\| under H~0~: ρ (Spearman\'s rank correlation coefficient)=0.

###### 

Effect Modification by Position‐Specific *TLR2* Methylation Level on the Association Between PM~2.5~ Exposure and HRV, Adjusted for Cell Types

  Position   \% Change[\*](#tf11-4){ref-type="table-fn"}, Original Model, N=500[\*](#tf11-1){ref-type="table-fn"}   \% Change[\*](#tf11-4){ref-type="table-fn"}, Adjusted for Cell Types, N=498[\*](#tf11-2){ref-type="table-fn"}
  ---------- ------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------
  HR                                                                                                                
  1          0.05                                                                                                   0.03
  2          0.17                                                                                                   0.26
  3          0.53                                                                                                   0.60
  4          0.36                                                                                                   0.44
  5          0.83[\*](#tf11-3){ref-type="table-fn"}                                                                 0.85[\*](#tf11-3){ref-type="table-fn"}
  rMSSD                                                                                                             
  1          −10.07[\*](#tf11-3){ref-type="table-fn"}                                                               −9.64[\*](#tf11-3){ref-type="table-fn"}
  2          −5.60[\*](#tf11-3){ref-type="table-fn"}                                                                −6.10[\*](#tf11-3){ref-type="table-fn"}
  3          −7.35[\*](#tf11-3){ref-type="table-fn"}                                                                −7.45[\*](#tf11-3){ref-type="table-fn"}
  4          −6.55[\*](#tf11-3){ref-type="table-fn"}                                                                −6.48[\*](#tf11-3){ref-type="table-fn"}
  5          −8.29[\*](#tf11-3){ref-type="table-fn"}                                                                −7.88[\*](#tf11-3){ref-type="table-fn"}
  SDNN                                                                                                              
  1          −5.34[\*](#tf11-3){ref-type="table-fn"}                                                                −5.01[\*](#tf11-3){ref-type="table-fn"}
  2          −0.34                                                                                                  −0.72
  3          −3.87[\*](#tf11-3){ref-type="table-fn"}                                                                −3.97[\*](#tf11-3){ref-type="table-fn"}
  4          −1.62                                                                                                  −1.56
  5          −4.58[\*](#tf11-3){ref-type="table-fn"}                                                                −4.21[\*](#tf11-3){ref-type="table-fn"}
  LF                                                                                                                
  1          −2.45                                                                                                  −1.65
  2          1.75                                                                                                   1.39
  3          −8.77[\*](#tf11-3){ref-type="table-fn"}                                                                −8.90[\*](#tf11-3){ref-type="table-fn"}
  4          −1.22                                                                                                  −1.23
  5          −7.09                                                                                                  −6.46
  HF                                                                                                                
  1          −9.72                                                                                                  −8.72
  2          −5.31                                                                                                  −6.35
  3          −11.01[\*](#tf11-3){ref-type="table-fn"}                                                               −11.31[\*](#tf11-3){ref-type="table-fn"}
  4          −7.63                                                                                                  −7.74
  5          −14.20[\*](#tf11-3){ref-type="table-fn"}                                                               −13.33[\*](#tf11-3){ref-type="table-fn"}

HF indicates high‐frequency power (0.15 to 0.4 Hz); HR, heart rate; HRV, heart rate variability; LF, low‐frequency power (0.04 to 0.15 Hz); PM~2.5~, particulate matter with aerodynamic diameter \<2.5 μm; rMSSD, root mean square of successive differences; SDNN, standard deviation of normal‐to‐normal intervals; *TLR2*,*Toll‐like receptor 2*.

Results were adjusted for age, body mass index, fasting glucose level, hypertension, smoking status, alcohol consumption, physical exercise, household income, medication use (β‐blocker, calcium channel blocker, angiotensin‐converting enzyme inhibitor), room temperature, outdoor apparent temperature, season, weekday, and visit date.

Results were adjusted for all covariates in the original model and the percentage of neutrophil and lymphocyte.

*P*≤0.05, statistically significant.

The additional percent change in HRV associated with 10 μg/m^3^ increase in PM~2.5~ concentration, compared to participants with one %5mC lower *TLR2* methylation level.

Discussion
==========

This study on a cohort of aging male Boston‐area residents demonstrated the adverse impact of short‐term PM~2.5~ exposure estimated at the home address on HRV. In addition, novel findings showed that individuals with higher methylation in the *TLR*2 gene promoter are more susceptible to reduced HRV after PM~2.5~ exposure, compared to those with lower methylation levels. Furthermore, higher flavonoid intake in the year preceding the examination significantly lowered *TLR*2 methylation, and attenuated the association between PM~2.5~ exposure and the LF measure of HRV.

PM exposure is a modifiable factor that contributes to cardiovascular morbidity and mortality, particularly in the acute exposure period, as emphasized by the recent American Heart Association statement on air pollution.^[@b2]^ Consistent with our previous study,^[@b30]^ we observed the strongest effect on HRV from PM~2.5~ among major types of air pollutants. The negative association between short‐term PM~2.5~ exposure and HRV has been repeatedly observed in general population samples,^[@b37]^ cardiac and hypertensive patients,^[@b38]^ asthmatic adults,^[@b39]^ young adults,^[@b40]^ and older adults,^[@b4],[@b30]^ as well as in a recent meta‐analysis of 29 different studies (N=18 667).^[@b41]^ The present study showed effects of PM~2.5~ exposure across 4 different indices of HRV, but not on HR. This finding suggests that short‐term PM~2.5~ exposure may affect the cardiac interbeat intervals before any appreciable influence is detected on HR. SDNN, a marker of the cyclic components, represents the total variability over the 7 minutes of ECG monitoring. LF variability is linked to the activity of both the sympathetic and parasympathetic nervous system, whereas HF and rMSSD are sensitive to high‐frequency heart period fluctuations and reflect the parasympathetic nervous activity. The HRV reductions associated with PM~2.5~ in these 4 indices may reflect pathophysiological changes in cardiac autonomic balance following exposure, which could be a potential mechanism linking air pollution and cardiac morbidity and mortality in the aging population.^[@b5]^

Many epidemiological studies^[@b4],[@b30]^ have presented a wide interindividual variability in responses to short‐term air pollution, possibly due to biological characteristics.^[@b7]^ For example, preexisting cardiac conditions, diabetes, and polymorphism of genes involved in endothelial function may confer higher susceptibility to autonomic dysfunction induced by PM~2.5~ exposure.^[@b4],[@b30]^ However, these characteristics are either nonmodifiable or already well‐recognized conditions with specific treatment guidelines. This study revealed that increased *TLR2* methylation is linked with intensified inflammatory responses, as reflected in elevated plasma IL‐8, intercellular adhesion molecule 1, and vascular endothelial growth factor level. In addition, we demonstrated that low *TLR2* methylation, an epigenetic mechanism ensuring immunoregulation, reduces the adverse effects of PM~2.5~ exposure on HRV. *TLR2* provides a critical line of protection by inducing regulatory T cells to limit immune‐mediated damage.^[@b13]--[@b14]^ Netea et al reported a 50% decrease in the number of CD4+CD25+ regulatory T cells accompanied by an impaired release of immunosuppressive cytokines in *TLR2* null mice compared with wild‐type mice, demonstrating the role of TLR2 in immunoregulation.^[@b14]^ These findings support our hypothesis that high *TLR2* methylation, an epigenetic process associated with suppressed *TLR2* expression, conveys susceptibility to PM exposure‐induced HRV reductions by decreasing immunoregulation.

Our data presented notable effect heterogeneity across the 5 CpG positions within the *TLR2* promoter region. The distance from position 1 to position 5 is \<20 base pairs; thus, these sites are likely to share most of the same functional complexes and traits (ie, CpG islands, DNaseI hypersensitivity, nuclease accessibility, and histone modifications \[UCSC genome browser\]) ([Figure 2](#fig02){ref-type="fig"}). However, differential methylation patterns across 5 positions have been observed in the ENCODE project, as identified by the Illumina Infinium Human Methylation 450 Bead Array platform. This suggests that variable methylation patterns exist at these sites even though the CpGs share common functional complexes.

*TLR2* methylation is sensitive to dietary and other behavioral factors.^[@b42]^ In particular, flavonoids, a major subtype of polyphenols, are established inhibitors for methylation‐induced gene silencing.^[@b17]--[@b18]^ Flavonoids inhibit the activity of DNA methyltransferase in a dose--response manner, reverse DNA methylation, and can reactivate silenced genes.^[@b17]--[@b18],[@b43]^ Our study showed that dietary flavonoid intake over the previous year is negatively associated with *TLR*2 methylation, indicating that adequate flavonoid intake may be essential to maintain a low, protective *TLR*2 methylation level. In addition, we showed that increased flavonoid intake alleviates the adverse effect of PM~2.5~ exposure on LF, and the effect modification is diminished when the model is adjusted for *TLR*2 methylation. This finding suggests that, at least in part, the average daily flavonoid intake over the preceding year affects individual susceptibility to postexposure HRV reduction by modulating *TLR*2 methylation level. However, formal mediation analysis was not performed in the present study due to the lack of appropriate statistical methodology to identify the potential pathway between 2 effect modifiers in repeated‐measure data.

We also investigated a group of methyl nutrients including folic acid, vitamin B12, and methionine, which are essential components in the 1‐carbon metabolism pathway that is expected to favor higher blood DNA methylation.^[@b19]^ However, no evidence to date demonstrates whether methyl nutrients can specifically modulate immune genes.^[@b44]^ Our analysis did not show significant correlation between methyl nutrients intakes and *TLR*2 methylation status. In our previously published study, PM~2.5~ was negatively associated with HRV in subjects with lower vitamin B12 and methionine intakes, but not in the higher‐intake groups. Our findings indicated that the effect modification by vitamin B12 and methionine intake reported in our previous study is likely to act through a different mechanism, independent of *TLR2* methylation.

This study has several strengths, including its prospective study design and relatively large sample size that enabled us to determine effect modifications by *TLR2* methylation and flavonoid intakes. To demonstrate the power of the present study, we performed simulation‐based power calculation using linear mixed‐effect models with compound symmetry covariance structure, accounting for covariates adjustments. Specifically, we generated 1000 simulated data sets, each with N=500 independent subjects, in which each subject had 2 (correlated) observations. The exposure, effect modifier, and outcome were assumed to be normally distributed. A random intercept linear mixed‐effect model (with compound symmetry correlation structure) was then fitted to each of the simulated data sets. Using effect sizes for both the main effect of PM~2.5~ exposure and the effect modification after adjustment for covariates estimated from our data, we expected to have \>90% power to detect the observed main effect of PM on HRV indices, and \>80% power to detect the observed effect modification by *TLR2* methylation and flavonoid intakes at α=0.05 level. Exposure misclassification, which is inherent in epidemiological studies on air pollution, is a limitation of the present study. Most previous studies relied on a few monitoring sites in the study area as surrogates for recent PM~2.5~ exposure history; that approach introduced measurement errors leading to underestimation of the effect.^[@b45]^ We reduced misclassification by using a novel, validated, hybrid prediction model to assess temporally and spatially resolved PM~2.5~ exposure level,^[@b24]^ and the observed effect size of PM~2.5~ exposure on HRV is larger compared to a previous study from the same cohort using monitoring site data.^[@b4]^ This prediction model accounted for the spatial variability of PM~2.5~ concentration within the study area and produced more accurate estimates of recent PM~2.5~ exposure at a 10×10‐km resolution. The Boston metropolitan area comprises 15 corresponding model grid cells, and the use of the cell‐specific predictions for each participant enabled us to assign different exposure levels to participants on a relatively small grid based on their residential areas.^[@b26]^ Although measurement error cannot be completely avoided, it was unlikely to be associated with participants\' HRV status. Therefore, misclassification is likely nondifferential and is expected to bias our result toward the null. Acknowledging that confounding is a critical concern in any observational study, we included in regression models an extensive list of covariates. We conducted further analysis to evaluate the sensitivity of our results to covariate specification, and our results were stable and robust. We also examined the correlation between 48‐hour and 1‐year moving average of PM~2.5~ to rule out the possibility that the observed effect was partially due to correlation of the 48‐hour moving average with long‐term exposure to PM~2.5.~ These 2 exposure metrics were not correlated (*R*^2^=0.07); therefore, the association between the 48‐hour moving average of PM~2.5~ and HRV was unlikely to be confounded by long‐term PM~2.5~ exposure. In addition, all HRV measures were conducted at the same time of the day to eliminate confounding due to diurnal variation. While residual confounding due to unmeasured variables is not unlikely, chances that the observed association and effect modification reflected bias resulting from residual confounding are minimized.

We acknowledge several other limitations in the present study. During the follow‐up of the present study---when data on PM exposure are available---there were 636 eligible Normative Aging Study participants ([Figure 1](#fig01){ref-type="fig"}). However, our analysis only included a study population of 573 participants due to missing PM exposure or HRV data. To examine whether the final analysis sample is different from the eligible population, we compared key baseline characteristics (age, race, physical activity, alcohol consumption, smoking status, hypertension, diabetes, and household annual income) between participants excluded in the final analysis due to missing exposure or outcome (N=63) and the participants for final analysis (N=573), and no significant difference was observed (data not shown). In addition, in the analysis investigating effect modification by *TLR2* methylation, 73 of 573 participants were excluded due to lack of DNA samples for methylation analysis. In the analysis of flavonoid intake and *TLR2* methylation, 60 of 573 participants were excluded due to lack of FFQ data. However, based on the study operations, it is reasonable to assume that the missingness was independent of participants\' exposure level, HRV status, and methylation states. We compared the HRV measures between those with complete data (N=500/N=513) and those without (N=73/N=60), and no apparent difference was observed (data not shown). Therefore, selection bias due to informative missingness in this study was unlikely. Both the within‐person and between‐person effects contributed to the effect modification by *TLR2* methylation. However, during the study period, the effect modification by *TLR2* methylation was mostly due to between‐person effects, as when the models were adjusted for subject identification, the significance of effect modification was diminished (data not shown). Due to the limited number of within‐subject repeated visits, we were unable to identify the exact magnitude of effect modification by *TLR2* methylation within subject. In addition, our findings are limited to male older individuals who were residing in a lightly polluted urban area. Therefore, the conclusion might not be generalizable to young adults, females, or people living in other areas, due to differential environmental and physiological factors.

Finally, alveolar inflammation and the subsequent systemic inflammation are essential, but not the only mechanism linking PM~2.5~ exposure and cardiac dysfunction. For example, particles may perturb the autonomic nervous system balance via interaction with lung receptors; a small fraction of PM (ultrafine particles, and some PM constituents such as organic compounds and metals) may translocate into the systemic circulation.^[@b2]^ Due to the less‐than‐comprehensive analysis on plasma inflammatory marker profile and limited sample size, we were unable to draw a definite conclusion on the mechanistic pathway underlying the protective effect of low *TLR2* methylation status and high flavonoid intake. Future studies are warranted to identify the precise pathophysiological processes of PM‐induced cardiovascular responses, as well as the mechanistic underpinnings of the effect of *TLR2* methylation and dietary flavonoid intake.

The United States is an aging society, and older people are especially susceptible to air pollution--triggered cardiovascular disease. As air pollution remains an important ubiquitous public health threat, PM~2.5~‐associated HRV reduction is an alarming signal of influences on the autonomic regulation of heart rate in older people. These alterations may represent a primary sentinel effect to identify the influence of PM~2.5~ among older individuals or even reflect intermediate mechanisms that may favor acute cardiovascular events.^[@b2]--[@b3]^ Providing preventive strategies at the individual level is especially important in cardiovascular research, which was recognized as an important new emphasis in the American Heart Association statement on air pollution.^[@b2]^ Our study provides a novel perspective on individual susceptibility to adverse cardiovascular effects following short‐term air pollution; our findings suggest high *TLR2* methylation as a modifiable "epigenetic predisposition" for cardiovascular responses that are associated with short‐term PM~2.5~ exposure in older people. In addition, based on our data, increasing flavonoid intake---which could be achieved by increasing intake of 1 or more of the major sources of dietary flavonoids (tea, beans, wine, berries, and citrus fruits)---may help maintain a low *TLR2* methylation level and mitigate PM~2.5~ exposure‐induced cardiovascular system impairment.

In summary, our findings suggest that the epigenetic regulation of *TLR2*‐related immunity may determine vulnerability of older individuals when confronted with air pollution peaks, and that adequate dietary flavonoid intake may ensure a protective epigenetic status against the adverse effects of PM~2.5~ exposure.
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